Lenvatinib is an oral kinase inhibitor that selectively inhibits receptor tyrosine kinases involved in tumor angiogenesis and tumor growth (e.g., VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor (FGFR)1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET) [34,35]. The gene discussed is FGFR3; the disease is neoplasm.